Fresh analysis indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a major medical journal shows that while overweight people can lose about a fifth of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying such treatments should be cognizant of the danger of fast weight regain when the treatment concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass in about 18 months.
Comparing Treatments
The analysis, which reviewed 37 of trials involving thousands of participants, compared the effects of the injectable medications with conventional dieting.
The team point out that people who shed pounds through diet and exercise generally see a slower creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Fast Regain
Experts propose the mode of action of the drugs explains the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Issue?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of relapse, the treatment might need to be ongoing.
This opinion is reinforced by drug manufacturers, who note that the results "highlight the persistent nature of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
People who have discontinued the jabs explain a intense return of hunger.
"It was like something flipping and I was suddenly ravenous," described an individual.
The struggle is worsened if individuals have not developed sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on combined behavioural management.
